Senior Leadership Team

We have assembled a world-class team that is committed to bringing new, life-changing medicines to the people who need them most.

Jodie Morrison

Chief Executive Officer

Jodie Morrison is the Chief Executive Officer of Cadent Therapeutics and is a member of Cadent’s Board of Directors. Prior to Cadent, Ms. Morrison served as interim Chief Executive Officer at Keryx Biopharmaceuticals, Inc. (managing the process leading to the merger with Akebia Therapeutics) and Acting Chief Operating Officer at Syntimmune (acquired by Alexion)…

Read Jodie’s Bio

Christopher Kenney, MD

Chief Medical Officer

Christopher Kenney is the Chief Medical Officer at Cadent Therapeutics and brings extensive clinic research experience within neuroscience in both industry and academic roles. He most recently served as Senior Vice President of Medical Affairs at Acorda Therapeutics and launched INBRIJA™, a novel inhaled treatment for Parkinson’s disease…

Read Christopher’s Bio

Tim Piser, PhD

Chief Scientific Officer

Tim Piser is the Chief Scientific Officer of Cadent Therapeutics and has passionately pursued the discovery and development of neuroscience therapeutics for almost two decades in big pharma and in biotech, most notably at AstraZeneca and FORUM Pharmaceuticals. There, he led neuropharmacology…

Read Tim’s Bio

John McBride

Chief Financial Officer

John McBride is Chief Financial Officer at Cadent Therapeutics. Prior to joining Cadent, Mr. McBride was Chief Financial Officer at Syntimmune where he was part of the senior team instrumental in the sale of the company to Alexion. Prior to that, he served as both Chief Operating Officer and Chief Financial Officer during his tenure at Tokai Pharmaceuticals Inc…

Read John’s Bio

Nicole Luosey

Vice President of Strategic and Program Operations

Nicole Luosey is the Vice President of Strategic and Program Operations at Cadent Therapeutics. Ms. Luosey most recently was Vice President, Program Management at Syntimmune where she led investor activities and diligence and integration efforts of the acquisition by Alexion…

Read Nicole’s Bio

Rob Gaffey

Vice President of Finance and Administration

Rob Gaffey is Vice President of Finance and Administration at Cadent Therapeutics.  Mr. Gaffey was most recently Vice President of Finance and Corporate Controller at Merrimack Pharmaceuticals.  Previously he served as Vice President of Finance at Dimension Therapeutics where he played a lead role…

Read Rob’s Bio

Dawn Wilson

Vice President of Clinical Operations and Development

Dawn Wilson is the Vice President of Clinical Operations and Development at Cadent Therapeutics. Ms. Wilson most recently was Vice President, Clinical Operations and Program Management at Albireo Pharma where she led the clinical operations team executing their phase 3 programs in orphan pediatric liver diseases…

Read Dawn’s Bio

Meet the Team

Chi-Li Chen, PhD

Associate Director of CMC Development

Taylor Copeland, BS

Senior HR Representative

Ed Christian, PhD

Executive Director of Translational Medicine

Noah Goodman

Executive Director of Business Development

Brent Jones

Associate Director, Clinical Operations

Abhijit Kamerkar, MS

Associate Director of CMC Development

Richard Lin, PhD, MPH

Associate Director of Biostatistics and Data Management

Siobhan O’Neill

Clinical Trial Associate

Sam Malekiani, MS

Director of Drug Development
Head of Toxicology

Holly Schlichting

Executive Assistant

Shaishav Shah

Senior Associate, Regulatory Affairs and Quality Assurance

Amber Trzeciak, MS

Executive Assistant, Patient Partnership and Advocacy Manager

Laura Victor, BA

Senior Clinical Trial Associate

Join Our Team!

We’re looking for visionaries who want to join our fun and passionate team of people.  

View Our Open Positions

Board Members

  • Peter Barrett, PhD
    Atlas Venture

  • David Grayzel, MD
    Atlas Venture

  • Tim Anderson
    Cowen Healthcare Investments

  • James Bristol, PhD

  • Mark McDade
    Qiming Venture Partners, US

  • Franz Hefti, PhD

  • Jodie Morrison
    Cadent Therapeutics

Clinical Advisors: Spinocerebellar Ataxia

  • Jeremy Schmahmann, MD
    Founding Director, Massachusetts General Hospital Ataxia Unit
    Professor of Neurology, Harvard Medical School
  • Susan Perlman, MD
    Director, Ataxia Center and Director, Neurogenetics Clinical Trials

  • Vikram Shakkottai, MD, PhD
    Associate Professor
    University of Michigan

  • Sheng-Han Kuo, MD
    Assistant Professor
    Columbia University

Clinical Advisors: Essential Tremor

  • Dietrich Haubenberger, MHSc, MD
    Director, Clinical Trials Unit

  • Rodger J. Elble, MD, PhD
    Director, Parkinson Disease and Movement Disorders Clinic
    SIU Medicine

  • Elan D. Louis, MD, MS
    Chief, Division of Movement Disorders
    Yale University

  • Sheng-Han Kuo, MD
    Assistant Professor
    Columbia University

  • William Ondo, MD
    Director, Movement Disorders Clinic
    Methodist Neurological Institute

Clinical Advisors: Schizophrenia

  • Daniel C. Javitt, MD, PhD
    Director, Division of Experimental Therapeutics
    Columbia University Medical Center/
New York State Psychiatric Institute

  • John H. Krystal, MD
    Chair, Department of Psychiatry
    Yale University School of Medicine

  • Mark Corrigan, MD
    Chairman of the Board, BlackThorn Therapeutics

  • Mark Bear, PhD
    Picower Professor of Neuroscience

  • Michael F. Green, PhD
    Distinguished Professor, Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA

Our Investors

We believe in a world that is free.

Without restraint or hesitation. One where our minds think big, where our bodies lead the way, and where we harness the passion and energy to discover new and exciting things.

We create breakthrough therapies for neurological and psychiatric conditions by restoring brain rhythms to natural harmony.

Contact Us